Table 3.
Current combination drug trials using multiple selective inhibitors, dual-targeted therapies, or multikinase inhibitors.
| Combination Drugs/Ongoing Trials: | Targets: | Trial Phase | ClinicalTrials.gov Identifier: | Cancer Treated |
|---|---|---|---|---|
| Ibrutinib + Venetoclax | EGFR + BCL2 | 2 | NCT03045328 | Refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) |
| Dabrafenib + Trametinib | EGFR + MEK | 1/2 |
NCT01767454 NCT02296996 |
Melanoma |
| Zotiraciclib | CDK, JAK2, FLT3 | 1/2 | NCT02942264 | Gliomas |
| Ruxolitonib + Thalidomide | JAK1/2, CRBN | 2 | NCT03069326 | PMF, post-PV MF, or post-ET MF |
| CA-4948 | FLT3, IRAK | 1/2 | NCT04278768 | AML |
| CA-4948 + Ibrutinib | FLT3, IRAK BTK | 1/2 | NCT03328078 | NHL, CLL, and Waldenstrom’s macroglobulinemia (WM) |
| CG-806 | BTK, FLT3 | 1a/b |
NCT04477291 NCT03893682 |
AML, CLL/SLL, NHL |
| Repotrectinib | ROS1, TRK, ALK | 1/2 | NCT03093116 | NTRK fusion tumors |
EGFR: epidermal growth factor receptor, BCL2: B-Cell receptor 2, MEK: mitogen-activated protein kinase, CDK: cycline-dependent Kinase, JAK1/JAK2: Janus Kinase 1 and 2, FLT3: Fms-like tyrosine kinase 3, IRAK: interleukin-1 receptor-associated kinase, BTK: Bruton’s Tyrosine Kinase, ROS1: ROS Proto-Oncogene 1, TRKA: tropomyosin receptor kinase A, ALK: Anaplastic Lymphoma Receptor Tyrosine Kinase.